Epitalon
A synthetic tetrapeptide (Ala-Glu-Asp-Gly) and analogue of epithalamin, a polypeptide isolated from pineal gland extracts in Soviet biomedical research from the 1970s onward. Reportedly investigated for telomerase activation and longevity; developed primarily by the Institute of Bioregulation and Gerontology in St. Petersburg. The evidence base includes some published human studies from that group, but independent replication by external research teams is limited.
Side effects & risks
Epitalon has not been evaluated in large-scale, randomised controlled trials in humans using Western regulatory standards. No comprehensive human safety profile has been established through peer-reviewed trials meeting international clinical research standards. The risk profile for human use is, in practical terms, unknown in the context of published Western clinical science.
The majority of human research on epitalon was conducted in the Soviet Union and post-Soviet Russia, primarily by the group of Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology. These studies — which include a number of human trials — did not consistently follow randomisation, blinding, or reporting standards that would be required by current ICH Good Clinical Practice guidelines. The quality and independence of this evidence base is difficult to evaluate without access to original protocols and data.
No serious adverse events have been reported in the published epitalon literature, including the Russian-authored human studies. However, the absence of reported adverse events in studies with methodological limitations should not be interpreted as equivalent to an established safety record.
Community reports of epitalon use describe injection-site discomfort as the most common complaint. A small subset report transient changes in sleep quality, which is biologically plausible given epitalon's proposed effects on pineal melatonin regulation. No systematic community-level adverse event data exists.
Epitalon is not approved for human therapeutic use in any major Western regulatory jurisdiction. Individuals obtaining it as a research chemical assume an undetermined risk profile.
Evidence summary
Latest studies
LCP2 mediates SUV39H1-driven cellular senescence-related chemoresistance in natural killer/T-cell lymphoma.
This study investigated why an aggressive blood cancer, natural killer/T-cell lymphoma, often stops responding to chemotherapy. Working with lab-grown resistant cancer cells and animal models, the researchers found that resistant cells had entered a dormant, aged-like state called senescence, and that low levels of a protein called LCP2 helped drive this resistance. They mapped the chain of molecular events involved. To test whether clearing these dormant cells could help, they used two compounds — Epitalon and chaetocin — as "senolytics" (agents that remove senescent cells). In the animal models, this combination partly eliminated the therapy-induced dormant cells, improved the cancer's response to chemotherapy, and eased the immune-suppressing environment around the tumor. Epitalon was used here only as one of two experimental tools, not studied on its own, and the work did not report its dosing or safety. The authors present LCP2 as a possible marker of resistance and suggest senolytics deserve further study for lymphoma that no longer responds to chemotherapy.
Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions.
This narrative review, published in the Journal of the American Academy of Orthopaedic Surgeons: Global Research & Reviews, examines a broad class of research compounds called therapeutic peptides and asks whether they might have a role in orthopaedic medicine — including bone, tendon, muscle, and nerve recovery. Researchers reviewed the published scientific literature on several peptides, including BPC-157, TB-500, GHK-Cu, ipamorelin, CJC-1295, tesamorelin, sermorelin, semax, selank, and epitalon. Each compound was evaluated for its proposed biological mechanism and its relevance to orthopaedic injury and recovery. The review found that these peptides appear to act on molecular pathways involved in tissue repair, inflammation resolution, and nerve signalling. Wound-healing peptides such as BPC-157, TB-500, and GHK-Cu were reported to promote blood vessel formation and tissue remodelling. Growth hormone-stimulating peptides like ipamorelin, CJC-1295, tesamorelin, and sermorelin were described as activating repair-related growth signals. Peptides such as epitalon were linked to cellular energy regulation, and neuroactive peptides like semax and selank were associated with nerve growth factor pathways. However, the authors explicitly noted that clinical trials in human orthopaedic patients are currently lacking. The mechanistic evidence reviewed comes primarily from laboratory and animal studies. No adverse event data specific to this review were reported in the...
Therapeutic peptides in gerontology: mechanisms and applications for healthy aging.
This narrative review, published in Frontiers in Aging, set out to summarise what is currently known about therapeutic peptides that may support healthy aging — covering how they work, what clinical applications have been studied, what the evidence shows, and what safety data exist. Researchers searched major scientific databases and regulatory records through January 2026 and selected 20 sources based on relevance and methodological quality. From those sources, they identified nine peptides targeting different aspects of aging: tirzepatide (metabolic function), epitalon (telomere biology), GHK-Cu (skin regeneration), BPC-157 and TB-500 (tissue repair), Semax (brain protection), CJC-1295 and ipamorelin (growth hormone signalling), and bremelanotide (sexual function). The review found that FDA-approved peptides — tirzepatide and bremelanotide — are supported by robust data from large clinical trials. The remaining investigational peptides showed promising signals in preclinical or limited human studies, but the authors noted these lack long-term safety data and rigorous independent validation. The review identified several important knowledge gaps: optimal dosing is not established for most investigational peptides, effects of combining peptides are poorly understood, and reliable biomarkers for tracking outcomes do not yet exist. The authors concluded that while therapeutic peptides offer diverse mechanistic approaches to aging biology, the investigational agents...
Community discussion
Community-reported · not verified
These are synthesised observations from public forum discussions. They are community-reported, not clinically verified, and should not inform any health decision. The peptide does not cure, treat, or prevent any condition based on these reports.
“Is there anything you can’t take with Epitalon?”
A user asks whether any supplements or compounds should be avoided while taking epitalon, prompting discussion of stacking and interaction considerations.
“Epitalon breakdown, the telomere peptide”
An overview post summarizing epitalon and its association with telomerase activity and longevity research, presented as a breakdown of the compound for the community.
“Epitalon a waste”
A skeptical thread questioning whether epitalon delivers any noticeable benefit, with the poster framing the compound as not worth the cost or effort.
“Looking for experiences with SS-31, MOTS-C, DSIP& Epitalon.”
A user solicits firsthand experiences with SS-31, MOTS-C, DSIP, and epitalon, a cluster commonly grouped under mitochondrial and longevity interests. Replies compare perceived energy and sleep effects, discuss cycling versus continuous use, and note that the human evidence for each is limited and largely early-stage.
“Help please on reconstituted epitalon pick up”
A user asks for help regarding the handling of reconstituted epitalon.
Reported protocols (with caveats)
| USE | ROUTE | COMMON DOSE | FREQUENCY | TYPICAL CYCLE |
|---|---|---|---|---|
| Longevity / anti-aging research use | SC or IM injection | 5–10 mg daily (during course) | Once daily | 10–20 days; 1–2 courses per year |
| Sleep quality (community-reported) | SC injection | 5 mg | Once daily | 10–14 days |
Frequently asked questions
- What are the known risks of epitalon?
- No large-scale, independently replicated human safety studies using current methodological standards have been published. The human research literature on epitalon comes primarily from one Russian research group and does not meet current Good Clinical Practice standards as assessed from English-language publications. Community reports describe injection-site discomfort and occasional sleep changes. No serious adverse events have been reported in the published literature. The risk profile is unknown in the context of Western clinical evidence standards.
- What is epitalon reported to do in the body?
- In cell-culture studies, epitalon has been associated with activation of telomerase and elongation of telomeres in human somatic cells (Khavinson et al., 2003, PMID 12937682). In animal models, it has been associated with reduced tumour incidence in spontaneous carcinogenesis studies. In limited studies from Russian research, pineal peptides of this class have been associated with normalisation of melatonin rhythm in elderly subjects (Korkushko et al., 2007, PMID 17969590). Independent replication of these findings by external research groups is limited.
- How strong is the evidence for epitalon?
- The evidence base is predominantly from one Russian research group and includes cell culture, animal models, and human studies with limited methodological transparency. The telomerase activation finding in cell culture is notable and has not been independently replicated. The human anti-aging and longevity studies lack the methodological detail in available English translations to evaluate rigorously. The evidence grade is preclinical to emerging; independent Western clinical trial data is absent.
- Is epitalon the same as epithalamin?
- No, but they are closely related. Epithalamin is a polypeptide extract from the pineal gland; epitalon is a synthetic tetrapeptide (Ala-Glu-Asp-Gly) believed to be the active component of epithalamin. Most of the early research was on epithalamin; later research by the same group focused on the synthetic epitalon sequence. The two compounds are treated as closely related but are not identical.
- Is epitalon legal to buy or use?
- Epitalon is not approved for human therapeutic use in the United States, Australia, Canada, the UK, or most of the EU. In most jurisdictions it is sold as a research chemical. Its regulatory status in the United States is in transition: epitalon was removed from the FDA Category 2 nominated bulk substances list approximately April 2026, and a PCAC review is scheduled for July 2026. Regulatory status varies by country and is subject to change; verify current status with a qualified legal or clinical professional.